Selected article for: "nucleic acid and risk assessment"

Author: Kim, Denny; Robertson, James S.; Excler, Jean-Louis; Condit, Richard C.; Fast, Patricia E.; Gurwith, Marc; Pavlakis, George; Monath, Thomas P.; Smith, Jonathan; Wood, David; Smith, Emily R.; Chen, Robert T.; Kochhar, Sonali
Title: The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
  • Cord-id: b24zlaqt
  • Document date: 2020_6_19
  • ID: b24zlaqt
    Snippet: Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of nucleic acid vaccines. This will facilitate the assessment by key stakeholders of potential safety issues and understanding of overall benefit-risk. The structured assessment provided by the template can also h
    Document: Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of nucleic acid vaccines. This will facilitate the assessment by key stakeholders of potential safety issues and understanding of overall benefit-risk. The structured assessment provided by the template can also help improve communication and public acceptance of licensed nucleic acid vaccines.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1